HCWB (HCW Biologics) ROC (Joel Greenblatt) %: 75.41% (As of Mar. 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $4.30
GF Value $43.79
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics ROC (Joel Greenblatt) %?

HCW Biologics HCWB -9.28% 39 ROC (Joel Greenblatt) % is 75.41% as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $43.79 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,325 Biotechnology companies, HCW Biologics ranks better than 76.98% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. HCW Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 75.41%.

The historical rank and industry rank for HCW Biologics's ROC (Joel Greenblatt) % or its related term are showing as below:

HCWB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -374.44   Med: -184.66   Max: -5.19
Current: -5.19

During the past 7 years, HCW Biologics's highest ROC (Joel Greenblatt) % was -5.19%. The lowest was -374.44%. And the median was -184.66%.

HCWB's ROC (Joel Greenblatt) % is ranked better than
76.98% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs HCWB: -5.19

HCW Biologics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 29.90% per year.


HCW Biologics  (NAS:HCWB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


HCW Biologics ROC (Joel Greenblatt) % Related Terms


HCW Biologics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for HCW Biologics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCW Biologics ROC (Joel Greenblatt) % Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -374.44 -221.04 -158.11 -133.03 -30.64

HCW Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.22 -28.14 -78.20 17.44 75.41

HCWB vs KAPA, IMNN, MTVA: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, HCW Biologics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's ROC (Joel Greenblatt) % falls into.


HCWB
39GF Score
HCW Biologics Inc HCWB
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.032 + 0 + 0.3) - (14.253 + 0 + 0.00099999999999767)
=-13.922

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.075 + 0 + 0.417) - (12.912 + 0.47 + 0)
=-12.89

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of HCW Biologics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=15.704/( ( (20.881 + max(-13.922, 0)) + (20.766 + max(-12.89, 0)) )/ 2 )
=15.704/( ( 20.881 + 20.766 )/ 2 )
=15.704/20.8235
=75.41 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 75.41% mean?
HCW Biologics (HCWB) has a ROC (Joel Greenblatt) % of 75.41% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #305 out of 1325 companies in the Biotechnology industry, placing it in the top 23%.
Is HCW Biologics' ROC (Joel Greenblatt) % too high?
HCW Biologics' current ROC (Joel Greenblatt) % is 75.41%. Based on the distribution chart, HCW Biologics ranks #305 out of 1325 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' ROC (Joel Greenblatt) % compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #305 out of 1325 companies for ROC (Joel Greenblatt) %. This places HCW Biologics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HCW Biologics and its competitors. HCW Biologics's current ROC (Joel Greenblatt) % is 75.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.79, compared to a current price of $4.30 — trading 90.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 75.41%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current ROC (Joel Greenblatt) % is 75.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $4.30 is trading 90.2% below its estimated GF Value™ of $43.79. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • ROC (Joel Greenblatt) %: 75.41%
  • GF Value™: $43.79 vs. price of $4.30 (90.2% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price
$43.79
GF Value